6 Genome Sequencing Stocks to Buy for Big Health-Care Profits

Genome sequencing – basically figuring out the order of DNA, the building blocks of life – was once essentially little more than a lab exercise.

(Image credit: Getty Images)

Genome sequencing – basically figuring out the order of DNA, the building blocks of life – was once essentially little more than a lab exercise. But now, it has reached commercial viability and then some.

The field of genomics goes back to the 1950s, though it really started in earnest with the start of the Human Genome Project in 1990 – a 13-year, $2.7 billion enterprise that was completed in April 2013.

Genome sequencing, in which scientists and their myriad machines detail the entire set of human DNA, has fantastic medical potential, allowing researchers to find genetic mutations – errors that can be harmless at times, but other times debilitating or even fatal. Moreover, genome sequencing is starting to reach realistic pricing – the costs have fallen down to about $1,000 at the low end, and companies are racing to cash in on the myriad opportunities.

Here are six genome sequencing stocks to buy for this emerging medical technology. While genomics isn’t the biggest investing buzzword today, this is a promising niche of the market that could take off as it gains more prominence.

Data is as of Dec. 20, 2018.

Ken Berman
Contributing Writer, Kiplinger.com
Email: ken.berman@gorillatrades.com
Website: gorillatrades.com (opens in new tab)
LinkedIn: Gorilla Trades (opens in new tab)
Phone: (866) 222-6639

Ken Berman has been buying and selling stocks since he was a teenager and met with early success trading then-fledgling biotech stocks like Amgen, Biogen and Immunex. He later became a broker and worked for two wire houses, where he developed a proprietary system for buying and selling equities. In 1999, Mr. Berman formalized his method under the Gorilla Trades name and now has subscribers in the U.S. and 55 other countries around the world.